Updated data from a more mature October 2026 data cutoff show rapid and deep responses, with a 39% confirmed ORR, median duration of response of 9.2 months and median PFS of 6.7 months Clinical activity consistent across HPV status and prior-treatment subgroups, with a manageable safety profile Results support advancement of MICVO into the global Phase 3 HeadlinerSM trial in 2L+ R/M HNSCC, planned to initiate in mid-2027 Company to host a live webcast on November 19, 2026, at 7:00 a.m. EST, foll
Pyxis Oncology update: The MICVO oncology drug shows promising early data; dosage optimization is ahead. Click for more on PYXS stock.
Pyxis Oncology (PYXS) has priced a public offering of common stock and warrants for expected gross p
BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced the pricing of its previously announced registered public offering (the "Offering") of 36,047,919 shares of its common stock, or in lieu of common stock to certain investors, 1,883,121 pre-funded warrants to purchase shares of common stock, and accompanying common warrants to purchase 49,310,352 shares of
BOSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it has commenced a registered public offering (the "Offering") of (i) shares of its common stock, or in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock, and (ii) accompanying common warrants to purchase shares of common stock. Each share of common stoc
Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.
Pyxis Oncology receives a "Sell" rating due to high risk, an unproven pipeline, and looming cash constraints. Click here to read more on PYXS.
Detailed price information for Pyxis Oncology Inc (PYXS-Q) from The Globe and Mail including charting and trades.
Pyxis Oncology (NASDAQ:PYXS) shares fell 7% on Tuesday after the biotechnology company released updated Phase 1 data for Micvotabart Pelidotin, or MICVO, in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Among 33 efficacy-evaluable patients receiving MICVO at 5.
Detailed price information for Pyxis Oncology Inc (PYXS-Q) from The Globe and Mail including charting and trades.
MICVO demonstrated rapid and deep responses, with a 36% confirmed objective response rate (cORR) and 94% disease control rate (DCR), with clinical activity observed across HPV status and prior-treatment subgroups Substantial survival outcomes include median progression-free survival (mPFS) of 6.2 months and 12-month overall survival (OS) probability of 79%, with clinical activity observed across HPV status and prior-treatment subgroups No new safety signals observed; tolerability profile expecte
Pyxis Oncology (PYXS) has an average rating of buy and mean price target of $7.22, according to anal
Event to be webcast live on September 9, 2026 at 7:30 a.m. ETBOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it will host a live webcast on September 9, 2026 at 7:30 a.m. Eastern Time to present updated clinical data from its ongoing Phase 1 monotherapy study evaluating micvotabart pelidotin (MICVO) in patients with second-line and beyond (2L+) rec
Pyxis Oncology's (PYXS) board appointed Thomas Civik as Chief Executive Officer and Chairman, from S
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Interim Chief Executive Officer and Director of Pyxis Oncology, will participate in fireside chats at three upcoming conferences. Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Thursday, September 10, 2026, at 10:15 a.m. ET.2026 Cantor Global Healthcare Conference in New Yor
This is the newest page. Registered accounts read further back.